Prospective study to investigate the resistant mechanism to afatinib treatment in EGFR mutation-positive non-small cell lung cancer
- Conditions
- ung Cancer
- Registration Number
- JPRN-UMIN000031845
- Lead Sponsor
- Kagoshima University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 26
Not provided
1)Patients with interstitial pneumonitis or pulmonary fibrosis 2)Patients with serious infection 3)Patients with unsteady angina or cardiac infarction 4)Patients with severe complication 5)Patients with active double cancer 6)Patients requiring medication influenced P glycoprotein 7)Patients with history of dosage afatinib 8)Patients with contraindication against afatinib 9)Patients with history of serious hypersensitivity or allergy 10)Pregnant, pregnancy suspect, nursing women, patients who plan to have a baby 11)Patients with complication with mental disease or a mind symptom, and are judged to have difficulty in participation in the study 12)Any other patients who are regarded as unsuitable for this study by the investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method